Your browser doesn't support javascript.
loading
Early outcomes for low-risk pediatric heart transplant recipients and steroid avoidance: A multicenter cohort study (Clinical Trials in Organ Transplantation in Children - CTOTC-04).
Lamour, Jacqueline M; Mason, Kristen L; Hsu, Daphne T; Feingold, Brian; Blume, Elizabeth D; Canter, Charles E; Dipchand, Anne I; Shaddy, Robert E; Mahle, William T; Zuckerman, Warren A; Bentlejewski, Carol; Armstrong, Brian D; Morrison, Yvonne; Diop, Helena; Iklé, David N; Odim, Jonah; Zeevi, Adriana; Webber, Steven A.
Afiliación
  • Lamour JM; Division of Pediatric Cardiology, Children's Hospital at Montefiore, Bronx, New York, New York. Electronic address: jlamour@montefiore.org.
  • Mason KL; Rho Federal Systems Division, Chapel Hill, North Carolina.
  • Hsu DT; Division of Pediatric Cardiology, Children's Hospital at Montefiore, Bronx, New York, New York.
  • Feingold B; Departments of Pediatrics and Clinical and Translational Science, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
  • Blume ED; Department of Pediatric Cardiology, Boston Children's Hospital, Boston, Massachusetts.
  • Canter CE; Division of Pediatric Cardiology, Washington University School of Medicine, St. Louis, Missouri.
  • Dipchand AI; Department of Paediatrics, Labatt Family Heart Center, Hospital for Sick Children, Toronto, Ontario, Canada.
  • Shaddy RE; Division of Pediatric Cardiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Mahle WT; Division of Pediatric Cardiology, Children's Healthcare of Atlanta, Atlanta, Georgia.
  • Zuckerman WA; Division of Pediatric Cardiology, Columbia University Medical Center, New York, New York.
  • Bentlejewski C; Division of Pediatric Cardiology, Columbia University Medical Center, New York, New York.
  • Armstrong BD; Rho Federal Systems Division, Chapel Hill, North Carolina.
  • Morrison Y; Rho Federal Systems Division, Chapel Hill, North Carolina.
  • Diop H; Rho Federal Systems Division, Chapel Hill, North Carolina.
  • Iklé DN; Rho Federal Systems Division, Chapel Hill, North Carolina.
  • Odim J; Transplantation Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
  • Zeevi A; Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Webber SA; Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee.
J Heart Lung Transplant ; 38(9): 972-981, 2019 09.
Article en En | MEDLINE | ID: mdl-31324444
ABSTRACT

BACKGROUND:

Immunosuppression strategies have changed over time in pediatric heart transplantation. Thus, comorbidity profiles may have evolved. Clinical Trials in Organ Transplantation in Children-04 is a multicenter, prospective, cohort study assessing the impact of pre-transplant sensitization on outcomes after pediatric heart transplantation. This sub-study reports 1-year outcomes among recipients without pre-transplant donor-specific antibodies (DSAs).

METHODS:

We recruited consecutive candidates (<21 years) at 8 centers. Sensitization status was determined by a core laboratory. Immunosuppression was standardized as follows Thymoglobulin induction with tacrolimus and/or mycophenolate mofetil maintenance. Steroids were not used beyond 1 week. Rejection surveillance was by serial biopsy.

RESULTS:

There were 240 transplants. Subjects for this sub-study (n = 186) were non-sensitized (n = 108) or had no DSAs (n = 78). Median age was 6 years, 48.4% were male, and 38.2% had congenital heart disease. Patient survival was 94.5% (95% confidence interval, 90.1-97.0%). Freedom from any type of rejection was 67.5%. Risk factors for rejection were older age at transplant and presence of non-DSAs pre-transplant. Freedom from infection requiring hospitalization/intravenous anti-microbials was 75.4%. Freedom from rehospitalization was 40.3%. New-onset diabetes mellitus and post-transplant lymphoproliferative disorder (PTLD) occurred in 1.6% and 1.1% of subjects, respectively. There was no decline in renal function over the first year. Corticosteroids were used in 14.5% at 1 year.

CONCLUSIONS:

Pediatric heart transplantation recipients without DSAs at transplant and managed with a steroid avoidance regimen have excellent short-term survival and a low risk of first-year diabetes mellitus and PTLD. Rehospitalization remains common. These contemporary observations allow for improved caregiver and/or patient counseling and provide the necessary outcomes data to help design future randomized controlled trials.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Asunto principal: Trasplante de Corazón / Tacrolimus / Inmunosupresores / Ácido Micofenólico / Suero Antilinfocítico Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: J Heart Lung Transplant Asunto de la revista: CARDIOLOGIA / TRANSPLANTE Año: 2019 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Asunto principal: Trasplante de Corazón / Tacrolimus / Inmunosupresores / Ácido Micofenólico / Suero Antilinfocítico Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: J Heart Lung Transplant Asunto de la revista: CARDIOLOGIA / TRANSPLANTE Año: 2019 Tipo del documento: Article